Health Affairs March 24, 2023
Troyen A. Brennan

The high price of medications is driving many different policy initiatives aimed at providing relief for patients and health care payers. The Inflation Reduction Act is the most comprehensive example, as the federal government commences negotiation of prices with manufacturers for a limited number of medications. Other proposals are more focused, such as the cap on out-of-pocket spending for patients with diabetes in the Medicare Part D program who must purchase insulin. In the same vein, the state of California has recently sued insulin producers and pharmacy benefit managers, alleging unsound business practices and seeking relief for patients unable to afford insulin. Many other beneficiaries and payers are now getting relief from high prices through the so-called 340B program, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
It's Not Just Congress. There's Plenty of State-Level Action on PBMs, Drug Costs and Prices | AMCP 2024
Cullinan Nets $280M Investment and Targets CD19 in Lupus
Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too
On the Front Lines: Pharmacists' Role in Combating America's Opioid Epidemic
Fierce Biotech Layoff Tracker 2024: Ultimovacs says goodbye to 40% of staff; Major pharmas turn to layoffs

Share This Article